ISSN: 1859 - 2872
Effective evaluation of using intravenous bevacizumab in treatment of diabetic macular edema at 103 Military Hospital
Main Article Content
Keywords
Abstract
Objective: To assess the outcome and safety of intravitreous bevacizumab in treatment of diabetic macular edema patients at 103 Millitary Hospital. Subject and method: The clinical trial without a control group was carried out in 54 eyes (35 patients) with diabetic macular edema in Department of Ophthalmology at 103 Military Hospital. Intravitreous bevacizumab therapy was treated with PRN stratery. Result: The best corrected visual acuity gained significantly after 3 months, and gained 10.45 ± 2.21 letters after 12 months. Central macular thickness (CMT) with 1mm diameter reduced significantly after 3 months, and reduced 260.32 ± 54.05µm after 12 months. CMT with 6mm diameter also reduced significantly after 3 months, and reduces 87.32 ± 34.15µm after 12 months. The reductions of CMT 1mm were correlated with the improvement of BCVA (p=0.02, r = 0.41, Pearson’s test). The intra-injection complications were conjunctival hermorrhage (4.6%), corneal epithelium damage (2.4%). The post-injection complication was only uveitis (0.3%). There were no systemic complications such as hypertension, stroke. Conclusion: Intravitreous bevacizumab is an effective and safe therapy in treatment of diabetic macular edema.
Keywords: Diabetic macular edema, diabetes, bevacizumab.
Article Details
References
2. Lee R, Wong TY, and C Sabanayagam (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and vision 2(1): 17.
3. Das A, McGuire PG, and Rangasamy S (2015) Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology 122(7): 1375-1394.
4. Otani T, Yamaguchi Y, and Kishi S (2010) Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina 30(5): 774-780.
5. Mitchell P, Wong TY, and D.M.E.T.G.W. Group (2014) Management paradigms for diabetic macular edema. American journal of ophthalmology 157(3): 505-513.
6. Group AS and Group AES (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine 363(3): 233-244.
7. Wells JA et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine 372(13): 1193-1203.
8. Chen E et al (20100 Burden of illness of diabetic macular edema: Literature review. Current medical research and opinion 26(7): 1587-1597.
9. Cai S and Bressler NM (2017) Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings from DRCR. net Protocol T. Current opinion in ophthalmology 28(6): 636-643.
Article Sidebar
